Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124421 · ClinicalTrials.gov registry record · Phase 2
HOT: HIPEC in Ovarian Cancer as Initial Treatment
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by Mercy Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02124421 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is active but no longer recruiting, run by Mercy Medical Center. The registered enrollment target is 32 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02124421, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is active but no longer recruiting, sponsored by Mercy Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Questionnaire
- PROCEDURE Cytoreductive Surgery (CRS)
- DRUG Adjuvant Chemotherapy
- PROCEDURE Hyperthermic intraperitoneal chemotherapy
Study Locations (1)
Maryland
- Mercy Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-04 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02124421
The ClinicalTrials.gov registry entry for NCT02124421 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Mercy Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02124421 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02124421 about?
NCT02124421 is a clinical study titled "HOT: HIPEC in Ovarian Cancer as Initial Treatment". Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary perito...
What is the current status of trial NCT02124421?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-04. Estimated completion is 2028-04.
What conditions does trial NCT02124421 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT02124421?
The interventions under investigation include: Carboplatin (DRUG), Questionnaire (OTHER), Cytoreductive Surgery (CRS) (PROCEDURE), Adjuvant Chemotherapy (DRUG), Hyperthermic intraperitoneal chemotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT02124421?
This trial is sponsored by Mercy Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02124421 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.